Ryan H. Siurek - 08 Feb 2023 Form 4 Insider Report for BIODESIX INC (BDSX)

Role: Chief Accounting Officer
Signature: /s/ Robin H. Cowie as Attorney-in-Fact for Ryan H. Siurek
Issuer symbol: BDSX
Transactions as of: 08 Feb 2023
Net transactions value: -$3,627
Form type: 4
Filing time: 10 Feb 2023, 17:40:42 UTC
Previous filing: 21 Nov 2022
Next filing: 03 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BDSX	Common Stock	Options Exercise		+5,483	+23%		29,177	08 Feb 2023	Direct	F1
transaction	BDSX	Common Stock	Sale	$3,627	-2,016	-6.9%	$1.80	27,161	09 Feb 2023	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BDSX	Restricted Stock Units	Award	$0	+82,031		$0.000000	82,031	08 Feb 2023	Common Stock	82,031		Direct	F1, F4
transaction	BDSX	Restricted Stock Units	Options Exercise	$0	-1,927	-7.7%	$0.000000	23,120	08 Feb 2023	Common Stock	1,927		Direct	F1, F5
transaction	BDSX	Restricted Stock Units	Options Exercise	$0	-3,556	-33%	$0.000000	7,114	08 Feb 2023	Common Stock	3,556		Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock.
F2	These shares of Issuer's common stock were sold automatically to cover taxes upon the vesting of RSUs.
F3	The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.71 to $1.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
F5	These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
F6	These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.